GILD250103P78000
- 0.00
- 0.000.00%
Gilead Sciences Newsroom
Tuesday Market Pulls Back After Nvidia All Time High | Wall Street Today
Looking Into Gilead Sciences's Recent Short Interest
Market Sells CES Tech News, ISM Tuesday as Nvidia Champions Robots Monday | Live Stock
Gilead Sciences, Inc. (NASDAQ:GILD) Is a Favorite Amongst Institutional Investors Who Own 86%
RBC Trims Price Target on Gilead Sciences to $83 From $84, Keeps Sector Perform Rating
Hookipa Shareholder Gilead Sciences to Back Poolbeg Merger
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today
Market Climbed Monday Just Past Santa Rally High Water Mark | Wall Street Today
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
CES Tech Conference Week Starts with Nvidia and Chips Climbing | Live Stock
Citi's Themes: Top Stocks in AI, Leisure, Fin-tech, Video Gaming, Etc. Vs. Their SA Quant Ratings
Gilead Sciences, Inc. (GILD): A Bull Case Theory
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Gilead Buys $20.1 Million of Assembly Biosciences Stock -- Barron's
Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors
Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz
Friday? More Like Grinch Day | Wall Street Today
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Santa Claus Came Without Rallying the Troops | Live Stock
Gilead (GILD.US) has received approval for the long-acting HIV treatment "Lenacapavir" to be marketed in China.
The official NMPA website shows that Gilead's (GILD.US) HIV therapy, Lenacapavir tablets and Lenacapavir injection, has received marketing approval.